** Sun Pharmaceutical Industries’ Halol drug manufacturing plant may need four - six months to be cleared by the U.S. Food and Drug Administration (FDA), Credit Suisse analysts write in a note
** Latest concerns raised by the FDA at Halol, Sun’s key factory in western India, are “not very serious” and the site’s approval may not require an FDA reinspection - CS
** Brokerage continues to rate its ‘focus list stock’ as ‘Outperform’ with a TP of 640 rupees
** Co said on Feb 23 that FDA has issued form 483 with 3 observations for Halol facility
** Sun has been making remediations at the Halol site since 2015, when the FDA issued a warning letter for failing manufacturing standards there.
** 15 of 38 brokerages rate the stock “buy” or higher, 12 “hold” and 11 “sell” or lower; their median PT is 550 rupees